Wall Street Beat
Electromed Inc. (NSDQ:ELMD) plans to switch from the Nasdaq Capital Market exchange to NYSE Amex beginning next month.
The New Prague, Minn.-based airway clearance device firm, which went public last year, will continue to trade under the ELMD ticker on the new exchange.
Electromed, Inc. to List on the NYSE Amex
NEW PRAGUE, Minn.–(BUSINESS WIRE)–Electromed, Inc. (NASDAQ: ELMD) today announced that its Board of Directors has voted to transfer its stock exchange listing from the NASDAQ Capital Market to the NYSE Amex. Electromed currently expects that its common stock will commence trading on the NYSE Amex on October 3, 2011 and will continue to be listed under the ticker symbol “ELMD.” Until it begins trading on the NYSE Amex, Electromed’s common stock will continue to trade on the NASDAQ Capital Market.
The $10 million deal for Calypso Medical Technologies by Varian Medical Systems (NYSE:VAR) leaves a lot to be desired for Calypso’s legacy investors – namely, about $140 million.
Backers have poured more than $150 million into the Seattle-based company and its tumor-tracking technology since its 1999 inception.
Kips Bay Medical Inc. (NSDQ:KIPS) shares sank hard and fast on news that the FDA asked for additional information before allowing its eSVS surgical mesh to undergo clinical testing.
The Minneapolis-based company lost 34 percent yesterday, closing at $1.87 (compared to a close of $2.85 on Sept. 20). Along the way, shares hit an all-time low of $1.79.
A change to the way the LifeVest is reimbursed by Medicare would affect just 8 percent of Zoll Medical Corp.’s (NSDQ:ZOLL) total sales, CEO Richard Packer told a group of analysts Wednesday.
Moody’s assigns Ba2 rating to $960M in Fresenius notes
Boston Business Journal by Julie M. Donnelly , email@example.com
Date: Wednesday, September 14, 2011, 3:38pm EDT
Moody’s Investors Service has assigned a definite Ba2 rating to about $960 million in bonds issued by finance companies wholly owned by Fresenius Medical Care AG & Co. KGaA (NYSE: FMS), a Germany-based global provider of dialysis services.
The company’s North American operations are headquartered in Waltham, Mass.
It’s been a rough end of the summer on The Street for Zoll Medical Corp. (NSDQ:ZOLL), which has seen its share price cut nearly in half over the past six weeks.
On August 1 shares of the Chelmsford, Mass.-based resuscitation company hit an all-time high of $70.82 during midday trading on Wall Street. Investors, buoyed by the company’s strong earnings results, helped push the stock price to new heights.
A 1-for-6 reverse stock split worked out for NeuroMetrix Inc. (NSDQ:NUROD), which said today that it’s back in the good graces of the NASDAQ exchange, and announced a new product launch for the diabetes market.
The Waltham, Mass.-based company, a former high flier on Wall Street, has fallen back to earth after hitting a high-water mark of $39.35 per share in August 2006.
Boston Scientific Corp.’s (NYSE:BSX) newly appointed CEO Michael Mahoney signed on with a generous compensation package including a $2.25 million sign-on bonus in addition to his $900,000 base salary.
His offer letter, which also includes $16.7 million in long-term incentives through deferred stock and equity awards, is potentially worth nearly $20 million, according to SEC filings.